1. Department of Pharmacy, Guizhou Provincial People��s Hospital, Guiyang 550002, China; 2. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China; 3. Key Laboratory of Optimal Utilization of Natural Medicine Resources, Guizhou Medcial University, Guiyang 550004, China
Abstract��OBJECTIVE To establish a population pharmacokinetics(PPK) model of vancomycin in adult patients and investigate the factors influencing vancomycin clearance.METHODS The nonlinear mixed-effect model(NONMEM) was used to investigate the population characteristics of vancomycin in adult patients and the serum cystatin C was used as a marker of renal function. The final model was built by forward inclusion approach and backward elimination method. Fitting effect of the model was evaluated by the goodness of fit plots(GOFs). Nonparametric Bootstraps and normalized prediction distribution errors(NPDE) were performed to evaluate the robustness and predictive efficacy of the final model. External model evaluation was conducted using an independent dataset to evaluate the model predictability. RESULTS Vancomycin PPK model was set up via 147 serum trough concentration data from 95 adult patients. The estimated population typical values of clearance rate and apparent volume of distribution were 3.57 L��h-1 and 63.30 L, respectively. The main factor influencing clearance was renal function. The GOFs showed that the final model was stable and effective, and the fitting degree of the final model was better than that of the base model. The robust rate verified by Bootstrap was 99.45%. All of the relative biases between the median of parameters validated by Bootstrap and the estimated parameters of final model were within ��3%, and the 95% confidence intervals of these validated parameters did not include zero. The NPDE followed the N(0,1) distribution with a global adjust P value of 0.334, which indicated that the model had a high predictive accuracy. External evaluation was performed via an independent dataset of 40 concentration data from 20 patients. The mean prediction error(MPE) and mean absolute prediction error(MAPE) based on population predictions(PRED) was -1.90% and 24.34%, respectively. CONCLUSION Vancomycin PPK model established in the study is of as a good stability and high predictive accuracy, as a reference for developing individualized administration regimens.
ʢ����,���鴺,�Ʋ���,������,��ѩ,�ż���,Ǯ��,л��,����. ����������C���������ܵ����ù��Ⱥ��ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2018, 53(21): 1847-1855.
SHENG Chang-cheng, SHEN Xiang-chun, TANG Cai-lin, XIONG Shi-juan, BAI Xue, ZHANG Jia-xing, QIAN Xin, XIE Juan, JIAO Zheng. Analysis of Population Pharmacokinetics of Vancomycin Using Cystatin C as a Marker of Renal Function. Chinese Pharmaceutical Journal, 2018, 53(21): 1847-1855.
ACKERMAN B H, VANNIER A M, EUDY E B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response[J]. Antimicrob Agents Chemother, 1992,36(8):1766-1769.
[2]
LARSSON A J, WALKER K J, RADDATZ J K, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions[J]. J Antimicrob Chemother, 1996,38(4):589-597.
[3]
LOWDIN E, ODENHOLT I, CARS O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 1998,42(10):2739-2744.
[4]
HOWDEN B P, WARD P B, CHARLES P GP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility[J]. Clin Infect Dis, 2004,38(4):521-528.
[5]
SAKOULAS G, GOLD H S, COHEN R A, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteraemia[J]. J Antimicrob Chemother, 2006,57(4):699-704.
[6]
VAN HAL S J, PATERSON D L, LODISE T P. Systematic review and Meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter[J]. Antimicrob Agents Chemother, 2013,57(2):734-744.
[7]
LIU C, BAYER A, COSGROVE S E, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-e55.
[8]
RYBAK M, LOMAESTRO B, ROTSCHAFER J C, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm, 2009,66(1):82-98.
[9]
YE Z K, CHEN Y L, CHEN K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society[J]. J Antimicrob Chemother, 2016,71(11):3020-3025.
[10]
YE Z K, LI X G, ZHAI S D. Therapeutic drug monitoring of vancomycin in China: current status andevaluation[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2013,29(7):545-548.
[11]
FANG J, HE L, CHEN Q J. Discussion of vancomycin dosage in Chinese adult patien[J]. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2014, 14(4):291-294.
[12]
SHENG C C, XIE J, ZHANG J X, et al. Clinical application and serum concentration monitoring of vancomycin:analysis of 202 cases[J]. Drug Eval Res(ҩ�������о�), 2016, 39(4):589-593.
[13]
MULLA H, POOBONI S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation[J]. Br J Clin Pharmacol, 2005,60(3):265-275.
[14]
ZHAO W, ZHANG D, FAKHOURY M, et al. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease[J]. Antimicrob Agents Chemother, 2014,58(6):3191-3199.
[15]
STOCKMANN C, SHERWIN C M, ZOBELL J T, et al. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis[J]. Pharmacotherapy, 2013,33(12):1288-1296.
[16]
REVILLA N, MARTIN-SUAREZ A, PEREZ M P,et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation[J]. Br J Clin Pharmacol, 2010,70(2):201-212.
[17]
OKADA A, KARIYA M, IRIE K, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation[J]. J Clin Pharmacol, 2018,58(9):1140-1149.
[18]
ALQAHTANI S A, ALSULTAN A S, ALQATTAN H M, et al. Population pharmacokinetic model for vancomycin used in open heart surgery: model-based evaluation of standard dosing regimens[J]. Antimicrob Agents Chemother, 2018, 62(7):e00088-18.
[19]
DENG C H, LIU T T, ZHOU T Y, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis[J]. Int J Clin Pharmacol Ther, 2013,51(5):407-415.
[20]
HE X R, LIU Z H, JI S M, et al. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people[J]. Acta Pharm Sin(ҩѧѧ��), 2014, 49(11):1528-1535.
[21]
CHEN B, YANG W H, ZHANG W X, et al. Population pharmacokinetics model of vancomycin in Chinese adult patients[J]. Pharm Clin Res(ҩѧ���ٴ��о�), 2013, 21(6):605-609.
[22]
LI J J, LIU Y X, TANG L, et al. Population pharmacokinetics of vancomycin in Chinese neonates[J]. Chin Pharm J(�й�ҩѧ��־), 2017,52(16):1434-1441.
[23]
SONG L, TIAN X J, TIAN W J, et al. Population pharmacokinetic study of vancomycin in neonatal and infantpatients[J]. Chin J New Drugs Clin Rem(�й���ҩ���ٴ���־), 2017,36(4):215-220.
[24]
DENG C H, JI S M, WANG S Y, et al. Development of therapeutic drug monitoring software of vancomycin for adult patients[J]. Chin Pharm J(�й�ҩѧ��־), 2014,49(10):881-885.
[25]
SHENG C C, XIE J, XIONG S J, et al. Determination of vancomycin in human serum using reversed phase high performance liquid chromatography[J]. Guizhou Med J(����ҽҩ), 2016, 40(4):372-374.
[26]
INKER L A, SCHMID C H, TIGHIOUART H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med, 2012,367(1):20-29.
[27]
ZHANG C, SHAN A L. Population pharmacokinetic model development[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2013, 29(11):803-806.
[28]
YE H B, RUI J Z. Bootstrap validation and its application in population pharmacokinetic studies with NONMEM[J]. J Med Postgr(ҽѧ�о���ѧ��), 2010, 23(12):1314-1318.
[29]
ZHANG C, SHAN A L. Model validation and simulation of population pharmacokinetics[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2013, 29(12):883-886.
[30]
COMETS E, BRENDEL K, MENTRE F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R[J]. Comput Methods Programs Biomed, 2008,90(2):154-166.
[31]
OWEN J S, FIEDLER-KELLY J. Introduction to Population Pharmacokinetic/Pharmacodynamic Analysis with Nonlinear Mixed Effects Models[M]. Hoboken: John Wiley & Sons, Inc., 2014:214-217.
[32]
LIAO Y M, LIU T T, CHENG D H, et al. Estimation of cystatin C as a marker of renal function to predict serum trough concentrations of vancomycin[J]. Herald Med(ҽҩ����), 2015, 34(6):730-732.
[33]
WU S W. Value of serum cystatin C level in renal function evaluation[J]. Hebei Med J(�ӱ�ҽҩ), 2010, 32(17):2365-2366.
[34]
HUANG X, XU D M. Pharmacotherapy of Renal Disease(����ҩ������ѧ) [M]. Beijing: Chemical Industry Press, 2010:105.
[35]
XU G B, LI Z Y. Emphasis on the utility of laboratoryexamination on early diagnosis of chronic kidney disease[J]. Chin J Lab Med(�л�����ҽѧ��־), 2006, 29(11):961-965.
[36]
DONADIO C, KANAKI A, CAPRIO F, et al. Prediction of glomerular filtration rate from serum concentration of cystatin C: comparison of two analytical methods[J]. Nephrol Dial Transplant, 2012,27(7):2826-2838.
[37]
BARNFIELD M C, BURNISTON M T, REID U, et al. Cystatin C in assessment of glomerular filtration rate in children and young adults suffering from cancer[J]. Nucl Med Commun, 2013,34(6):609-614.
[38]
ASILIOGLU N, ACIKGOZ Y, PAKSU M S, et al. Is serum cystatin C a better marker than serum creatinine for monitoring renal function in pediatric intensive care unit?[J]. J Trop Pediatr, 2012,58(6):429-434.
[39]
WASE��N E, SUOMINEN P, ISOAHO R, et al. Serum cystatin C as a marker of kidney dysfunction in an elderly population[J]. Clin Chem, 2002,48(7):1138-1140.
[40]
DHARNIDHARKA V R, KWON C, STEVENS G. Serum cystatin C is superior to serum creatinine as a marker of kidney function a Meta-analysis[J]. Am J Kidney Dis, 2002,40(2):221-226.
[41]
SI T Y, HUANG P P. Analysis of correlation between serum cystatin C, blood creatinine and creatinine clearance rate in patients with different functional impairments[J].J Guangdong Med Coll(�㶫ҽѧԺѧ��), 2004, 22(2):137-138.
[42]
TANAKA A, AIBA T, OTSUKA T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function[J]. Antimicrob Agents Chemother, 2010,54(2):778-782.
[43]
CHUNG J Y, JIN S J, YOON J H, et al. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations[J]. J Korean Med Sci, 2013,28(1):48-54.
[44]
DECAROLIS D D, THORSON J G, MARRAFFA R A, et al. Comparison of equations with estimate renal function to predict serum vancomycin concentration in patients with spinal cord injury-does the use of cystatin C improve accuracy?[J]. Ther Drug Monit, 2014,36(5):632-639.
[45]
MARQUES-MINANA M R, SAADEDDIN A, PERIS J E. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline[J]. Br J Clin Pharmacol, 2010,70(5):713-720.
[46]
SEAY R E, BRUNDAGE R C, JENSEN P D, et al. Population pharmacokinetics of vancomycin in neonates[J]. Clin Pharmacol Ther,1994,56(2):169-175.
2018, Vol. 53 
